TriangleKQB198 (NCT07406633)
KQB198 trial for GIST - Gastrointestinal Stromal Tumor (NCT07406633). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable or metastatic gastrointestinal stromal tumors starting first-line treatment. A KIT or PDGFRA mutation is required; KIT exon nine and PDGFRA D842V mutations are excluded.
The idea: imatinib blocks growth-signaling proteins, including KIT and PDGFR. Researchers add the experimental drug KQB198 to test tumor response, safety, and drug levels. Both drugs are taken by mouth. Earlier imatinib around surgery is allowed only if it stopped more than a year ago.
This phase 2 study plans 46 patients. Kumquat Biosciences sponsors it; seventeen US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.